Project Grant R01AI183391
Award Date 9/24/25
Completion Date 8/31/27
Dollars Obligated $61K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Thailand
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $202,055.00 to Harvard T.H. Chan School of Public Health to characterize the Plasmodium falciparum apicomplexan amino acid transporter 2 (PfAPAT2) and its proline transport capability. The research aims to understand the role of PfAPAT2 in regulating proline levels in the malaria parasite, which can impact its sensitivity to certain...
- This $258,644 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to develop novel 4-aminoquinoline therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The grant recipient, Oregon Health & Science University, will use an iterative medicinal chemistry approach to select compounds with potent antiplasmodial activity, favorable pharmacokinetic...
- The National Institute of Child Health and Human Development (NICHD), through the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded a $1,486,976 project grant to Oregon Health & Science University (OHSU) to examine the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa. The project aims to investigate alternative antimalarial treatments, such as dihydroartemisinin-piperaquine (DP), that could potentially...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will provide $187,056 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the role of erythrocyte glycolysis in the Plasmodium falciparum lifecycle as a potential antimalarial strategy. The research aims to determine how disrupting erythrocyte glycolysis affects the growth and progression of...
- This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $705,896 to the University of Notre Dame to investigate emerging artemisinin partner drug resistance in Eastern Africa. The key objectives are to: Conduct a detailed analysis of in vitro phenotypes and genome variation in P. falciparum isolates from African patients who failed artemether-lumefantrine (AL) treatment, creating a...
- This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
- This $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports the development of next-generation ELQ compounds for the treatment and prevention of malaria. The research aims to identify novel, rapidly acting anti-malarial drugs to target the blood and liver stages of the Plasmodium falciparum parasite, as well as formulations suitable for long-acting...
- The Project Grant titled "Impact of Antimalarials on Parasite Selection Through the Mosquito Vector" is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $192,364 award, which runs from August 2025 to July 2030, supports research at Yale University to investigate the effect of antimalarial drugs taken by humans on the development of malaria parasites within mosquitoes. The...
- This Project Grant award of $1,553,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a genomic surveillance approach for monitoring artemisinin resistance in Plasmodium falciparum malaria in Africa. The project aims to identify genetic mutations and altered biological functions associated with artemisinin resistance, which is a critical concern as resistance emerges...